Healthequity (HQY) Cost of Revenue (2013 - 2026)

Healthequity's Cost of Revenue history runs 14 years deep, the most recent figure standing at $98.3 million for Q2 2026.

• In Q2 2026, Cost of Revenue fell 7.7% year-over-year to $98.3 million; the TTM figure through Apr 2026 stood at $392.1 million (down 8.51% YoY), while the FY2026 annual figure was $400.3 million, down 5.25% from the prior year.
• Cost of Revenue for Q2 2026 stood at $98.3 million, down from $106.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $122.8 million in Q1 2025, with the low at $87.9 million in Q3 2022.
• The 5-year median for Cost of Revenue is $96.8 million (2022), against an average of $98.1 million.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue advanced 23.93% in 2025, then decreased 13.3% in 2026.
• Healthequity's Cost of Revenue stood at $88.8 million in 2022, then climbed by 1.43% to $90.0 million in 2023, then grew by 14.85% to $103.4 million in 2024, then fell by 9.0% to $94.1 million in 2025, then advanced by 4.49% to $98.3 million in 2026.
• Business Quant data shows HQY's Cost of Revenue at $98.3 million in Q2 2026, $106.4 million in Q1 2026, and $94.1 million in Q4 2025.